个人简历

2006-2010年在美国能源部-布鲁克海文(Brookhaven)国家实验室进行博士后期间，参与2项美国国立卫生院重大项目。目前，主持/完成3项国家自然科学基金，1项广西自然科学基金-重大项目，1项广西自然科学基金-杰出青年项目和2项广西自然科学基金-重点项目。广西高等学校高水平创新团队及卓越学者、广西自然科学基金-杰出青年；广西科学技术特别贡献奖（排名第3）和广西青年科技奖。独立开展工作以来，研究成果主要以通讯作者发表在Nature Communications、Molecular Pharmaceutics和Journal of Medicinal Chemistry等国际医学和生物权威期刊40余篇；受邀在Curr Top Med Chem 和 Curr Pharm Design 等国际权威医学刊物撰写综述；在Future Med Chem 和 Curr Pharm Design国际权威医学期刊撰写专题评论(Editorial Article)；担任美国化学会、Elsevier和Wiley等SCI国际刊物审稿专家,Curr Pharm Design 客座主编、The Open Medicinal Chemistry Journal 、The Open Clinical Biochemistry Journal和 Frontiers in Chemistry编委；授权国家发明专利7项\r
\r
学历背景\r
2006-2010 美国能源部-布鲁克海文国家实验室(Associate Researcher)\r
2003-2006 中国科学院福建物质结构研究所(博士)\r
2000-2003 广西师范大学化学与药学学院(硕士）\r
\r
工作经历\r
2010.12-至今， 广西师范大学化学与药学学院(教授)\r
2010.4-至今， 药用资源化学与药物分子工程国家重点实验室(学术带头人)\r
2012.3-至今， 广西师范大学研究生学院(副院长)

研究领域

"""""功能蛋白质导向的金属药物研究\r
1、细胞迁移机制\r
2、基于蛋白质设计抗肿瘤药物\r
3、蛋白质载药体系"

近期论文

Yue JP, Zhang Y, Liang WG, Gou XW, Lee P, Liu H, Lyv WQ, Tang WJ, Yang F*, Liang H*, Wu XY*. In Vivo Epidermal Migration Requires Focal Adhesion Targeting of ACF7. Nature Communications. 2016, 7: 11692. (综合性顶级期刊)\r
\r
YL Ma, JP Yue, Y Zhang, CZ Shi, M Odenwald, WG Liang, Q Wei, A Goel, XW Gou, J Zhang, SY Chen, WJ Tang, JR Turner, F Yang*, H Liang*, HL Qin*, XY Wu*.ACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamics. Nature Communications. 2017, 8: 15375.\r
\r
Gou Y, Qi JX, Zhang Y, Jiang M, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing anticancer copper(II) pro-drugs based on the nature of cancer cells and human serum albumin carrier IIA subdomain. Molecular Pharmaceutics. 2015, 12: 3597-3609. (药剂学顶级期刊)\r
\r
Y Gou, Y Zhang, ZL Zhang, J Wang, ZP Zhou, H Liang*, F Yang*. Design of an anticancer copper(II) pro-drug based on the Lys199 residue of the active targeting human serum albumin nanoparticle carrier. Molecular Pharmaceutics. 2017, 14: 1861-1873.\r
\r
Qi JX, Zhang Y, Gou Y, Zhang ZL, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing an anti-cancer copper(II) pro-drug based on the His242 residue of the human serum albumin carrier IIA sub-domain. Molecular Pharmaceutics. 2016, 13: 1501−1507.\r
\r
Qi JX, Gou Y, Zhang Y, XY Wu, Yang F*, H Liang*. HSA-based multi-drug delivery systems for combination therapy of three anticancer agents. Molecular Pharmaceutics. 2016, 13: 3098-105.\r
\r
Yang F*, Yue J, Ma L, Ma Z, Li M, Wu X, Liang H*. Interactive associations of drug-drug and drug-drug-drug with IIA sub-domain of human serum albumin. Molecular Pharmaceutics. 2012, 9: 3259-65.\r
\r
Wang J, Gou Y, Zhang Z, Yu P, Qi J, Qin Q, Sun H, Wu X, Liang H, Yang F*. Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin. Molecular Pharmaceutics, 2018, 15: 2180-2193.\r
\r
Qi JX, Gou Y, Wu XY, T Wang, Yang F*. Developing anticancer ferric pro-drugs based on the N-donor residues of human serum albumin carrier IIA subdomain. Journal of Medicinal Chemistry, 2016, 59: 7497-511.(药物化学顶级期刊）\r
\r
Gou Y, Zhang Z, Li D, Zhao L, Cai M, Sun Z, Li Y, Zhang Y, Khan H, Sun H, Wang T, Liang H*, Yang F*. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single resistance in a breast cancer model. Drug Delivery, 2018, 25: 321-329.(IF=6.402)\r
\r
Designing pro-drugs based on special residues of human serum albumin. Curr Top Med Chem. 2016, 16: 996-1008. (医学SCI 2区)\r
\r
Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: Development of HSA carrier for metal-based drugs. Curr Pharm Design. 2015, 21: 1848-61. (医学SCI 2区)\r
\r
Interactive association of drugs binding to human serum albumin. Int J Mol Sci, 2014, 15: 3580-95. (IF=3.257)